INDIAN SNAKEROOT: Overview, Uses, Side Effects, Precautions, Interactions, Dosing and Reviews

Overview

Indian snakeroot (Rauvolfia serpentina) is an evergreen shrub found in Southeast Asia. The root is used as medicine. It's considered an endangered species.

Indian snakeroot contains small amounts of chemicals such as reserpine and yohimbine, which are prescription drugs that can cause serious side effects.

People use Indian snakeroot for high blood pressure, anxiety, constipation, malaria, insomnia, and many other conditions, but there is no good scientific evidence to support these uses.

Don't confuse Indian snakeroot with Rauvolfia vomitoria or Yohimbe. These are not the same.

Uses & Effectiveness

We currently have no information for INDIAN SNAKEROOT overview.

Side Effects

When taken by mouth: Indian snakeroot is possibly unsafe. It contains the drugs reserpine and yohimbine. Most side effects seem to be mild, but high doses might cause low blood pressure and slow heart rate. Long-term use can cause depression.

Special Precautions and Warnings

Pregnancy and breast-feeding: There isn't enough reliable information to know if Indian snakeroot is safe to use when pregnant or breast-feeding. Stay on the safe side and avoid use. The chemicals in Indian snakeroot can be passed to the unborn baby and into breast milk and might cause harm.

Anxiety: Indian snakeroot contains a chemical that might make anxiety worse. Use Indian snakeroot with caution if you have anxiety.

Depression: Indian snakeroot can cause depression, especially in people who have had depression before.

Shock therapy (electroconvulsive therapy, ECT): Indian snakeroot should not be used by people who are receiving ECT. Stop taking Indian snakeroot at least one week before beginning ECT.

Gallbladder disease: Indian snakeroot might make gallbladder disease worse. Use Indian snakeroot with caution if you have gallbladder disease.

Heart disease: Chemicals in Indian snakeroot can increase or decrease blood pressure. Use with caution if you have heart disease or are at risk for heart disease.

Pheochromocytoma: Avoid Indian snakeroot if you have this condition. It might increase the risk of dangerously high blood pressure.

Gastrointestinal (GI) conditions: Indian snakeroot can irritate the stomach and intestines. Don't use it if you have ever had peptic ulcers or other stomach disorders.

Interactions

Major Interaction

Do not take this combination

Digoxin (Lanoxin) interacts with INDIAN SNAKEROOT
Digoxin helps the heart beat more strongly. Indian snakeroot seems to slow the heartbeat. Taking Indian snakeroot along with digoxin might decrease the effects of digoxin. Do not take Indian snakeroot if you are taking digoxin.
Levodopa interacts with INDIAN SNAKEROOT
Levodopa is used for Parkinson disease. Taking Indian snakeroot along with levodopa might decrease the effects of levodopa. Do not take Indian snakeroot if you are taking levodopa.
Medications for mental conditions (Antipsychotic drugs) interacts with INDIAN SNAKEROOT
Taking Indian snakeroot along with some medications for mental conditions might increase the risk of side effects.
Medications for high blood pressure (Beta-blockers) interacts with INDIAN SNAKEROOT
Indian snakeroot might lower blood pressure. Taking Indian snakeroot along with medications that lower blood pressure might cause blood pressure to go too low. Monitor your blood pressure closely.

Moderate Interaction

Be cautious with this combination

Ephedrine interacts with INDIAN SNAKEROOT
Ephedrine can speed up the nervous system and make you feel jittery. Indian snakeroot might increase or decrease these effects from ephedrine.
Medications for depression (MAOIs) interacts with INDIAN SNAKEROOT
Indian snakeroot contains a chemical, called tyrosine, that affects the body. This chemical might increase the side effects of some medications used for depression.

Some common MAOIs include phenelzine (Nardil), selegiline (Zelapar), and tranylcypromine (Parnate).
Sedative medications (CNS Depressants) interacts with INDIAN SNAKEROOT
Indian snakeroot might cause sleepiness and slowed breathing. Some medications, called sedatives, can also cause sleepiness and slowed breathing. Taking Indian snakeroot with sedative medications might cause breathing problems and/or too much sleepiness.
Stimulant drugs interacts with INDIAN SNAKEROOT
Stimulants, such as amphetamines and cocaine, speed up the nervous system. By speeding up the nervous system, stimulant medications can increase blood pressure and speed up the heartbeat. Taking Indian snakeroot along with stimulant drugs might cause serious problems including increased heart rate and high blood pressure.
Medications changed by the liver (Cytochrome P450 2D6 (CYP2D6) substrates) interacts with INDIAN SNAKEROOT
Some medications are changed and broken down by the liver. Indian snakeroot might change how quickly the liver breaks down these medications. This could change the effects and side effects of these medications.
Medications for diabetes (Antidiabetes drugs) interacts with INDIAN SNAKEROOT
Indian snakeroot might lower blood sugar levels. Taking Indian snakeroot along with diabetes medications might cause blood sugar to drop too low. Monitor your blood sugar closely.
Medications for high blood pressure (Antihypertensive drugs) interacts with INDIAN SNAKEROOT
Indian snakeroot might lower blood pressure. Taking Indian snakeroot along with medications that lower blood pressure might cause blood pressure to go too low. Monitor your blood pressure closely.
Medications that slow blood clotting (Anticoagulant / Antiplatelet drugs) interacts with INDIAN SNAKEROOT
Indian snakeroot might slow blood clotting. Taking Indian snakeroot along with medications that also slow blood clotting might increase the risk of bruising and bleeding.
Medications for depression (Tricyclic Antidepressants) interacts with INDIAN SNAKEROOT
Taking some medications used for depression might alter the effects of Indian snakeroot and increase the risk for side effects.

Dosing

There isn't enough reliable information to know what an appropriate dose of Indian snakeroot might be. Keep in mind that natural products are not always necessarily safe and dosages can be important. Be sure to follow relevant directions on product labels and consult a healthcare professional before using.

View References

REFERENCES:

Roncaglia N, Locatelli A, Bellini P, and et al. A randomized controlled trial of ursodeoxycholic acid and S-adenosyl-L-methionine in the treatment of gestational cholestasis. Am J Obstet Gynecol 2000;182(1 pt 2):S167.

Rosenbaum, J. F., Fava, M., Falk, W. E., Pollack, M. H., Cohen, L. S., Cohen, B. M., and Zubenko, G. S. An open-label pilot study of oral S-adenosylmethionine in major depression. An interim report. Ala J Med Sci 1988;25(3):301-306. View abstract.

Rutjes, A. W., Nuesch, E., Reichenbach, S., and Juni, P. S-Adenosylmethionine for osteoarthritis of the knee or hip. Cochrane.Database.Syst.Rev. 2009;(4):CD007321. View abstract.

Salvadorini F, Galeone F, Saba P, and et al. Evaluation of S-adenosyl-L-methionine (SAMe) effectiveness on depression. Current Therapeutic Research 1980;27(6 section 2):908-917.

Santini, D., Vincenzi, B., Massacesi, C., Picardi, A., Gentilucci, U. V., Esposito, V., Liuzzi, G., La Cesa, A., Rocci, L., Marcucci, F., Montesarchio, V., Groeger, A. M., Bonsignori, M., and Tonini, G. S-adenosylmethionine (AdoMet) supplementation for treatment of chemotherapy-induced liver injury. Anticancer Res 2003;23(6D):5173-5179. View abstract.

Sarris, J. Clinical depression: an evidence-based integrative complementary medicine treatment model. Altern.Ther.Health Med. 2011;17(4):26-37. View abstract.

Scaggion, G., Baldan, L., Domanin, S., Sivo, M., Cenci, I., Beggio, R., and Castorina, G. [Antidepressive action of S-adenosylmethionine compared to nomifensine maleate]. Minerva Psichiatr. 1982;23(2):93-97. View abstract.

Scarzella R and Appiotti A. Confronto clinico in doppio cieco della SAMe versus clorimipramina nelle sindromi depressive. Rivista Sperimentale di Freniatria 1978;102:359-365.

Schaller, J. L., Thomas, J., and Bazzan, A. J. SAMe use in children and adolescents. Eur.Child Adolesc.Psychiatry 2004;13(5):332-334. View abstract.

Shippy, R. A., Mendez, D., Jones, K., Cergnul, I., and Karpiak, S. E. S-adenosylmethionine (SAM-e) for the treatment of depression in people living with HIV/AIDS. BMC.Psychiatry 11-11-2004;4:38. View abstract.

Silveri, M. M., Parow, A. M., Villafuerte, R. A., Damico, K. E., Goren, J., Stoll, A. L., Cohen, B. M., and Renshaw, P. F. S-adenosyl-L-methionine: effects on brain bioenergetic status and transverse relaxation time in healthy subjects. Biol.Psychiatry 10-15-2003;54(8):833-839. View abstract.

Stramentinoli, G. and Catto, E. Pharmacokinetic studies of SAMe in several animal species. Pharmacol Res Com 1976;8:211-218.

Stramentinoli, G. Pharmacologic aspects of S-adenosylmethionine. Pharmacokinetics and pharmacodynamics. Am J Med 11-20-1987;83(5A):35-42. View abstract.

Trespi A, Vigoni R, Matti C, and et al. TUDCA, UDCA and Ademetionine (Ade) in the treatment of alcohol-induced liver damage [abstract]. J Hepatol 1997;26:128.

Vendemiale, G., Altomare, E., Trizio, T., Le Grazie, C., Di Padova, C., Salerno, M. T., Carrieri, V., and Albano, O. Effects of oral S-adenosyl-L-methionine on hepatic glutathione in patients with liver disease. Scand J Gastroenterol 1989;24(4):407-415. View abstract.

Williams, A. L., Girard, C., Jui, D., Sabina, A., and Katz, D. L. S-adenosylmethionine (SAMe) as treatment for depression: a systematic review. Clin Invest Med 2005;28(3):132-139. View abstract.

Yang, J., He, Y., Du, Y. X., Tang, L. L., Wang, G. J., and Fawcett, J. P. Pharmacokinetic properties of S-adenosylmethionine after oral and intravenous administration of its tosylate disulfate salt: a multiple-dose, open-label, parallel-group study in healthy Chinese volunteers. Clin.Ther. 2009;31(2):311-320. View abstract.

Yousef, I. M., Barnwell, S. G., Tuchweber, B., Weber, A., and Roy, C. C. Effect of complete sulfation of bile acids on bile formation in rats. Hepatology 1987;7(3):535-542. View abstract.

Aggarwal R, Sentz J, Miller MA. Role of zinc administration in prevention of childhood diarrhea and respiratory illnesses: a meta-analysis. Pediatrics 2007;119:1120-30. View abstract.

Almasio P, Bortolini M, Pagliaro L, Coltorti M. Role of S-adenosyl-L-methionine in the treatment of intrahepatic cholestasis. Drugs 1990;40:111-23. View abstract.

Alpert JE, Papakostas G, Mischoulon D, et al. S-adenosyl-L-methionine (SAMe) as an adjunct for resistant major depressive disorder: an open trial following partial or nonresponse to selective serotonin reuptake inhibitors or venlafaxine. J Clin Psychopharmacol 2004;24(6):661-64. View abstract.

American Dental Association. "ADA Statement on FDA Toothpaste Warning Labels" https://www.ada.org/prof/prac/issues/statements/fluoride.html (Accessed 18 November 2002).

Ancarani E, Biondi B, Bolletta A, et al. Major depression complicating hemodialysis in patients with chronic renal failure: a multicenter, double-blind, controlled clinical trial of S-adenosyl-L-methionine versus placebo. Curr Ther Res 1993;54(6):680-6.

Arnold O, Saletu B, Anderer P, et al. Double-blind, placebo-controlled pharmacodynamic studies with a nutraceutical and a pharmaceutical dose of ademetionine (SAMe) in elderly subjects, utilizing EEG mapping and psychometry. Eur Neuropsychopharmacol 2005;15:533-43. View abstract.

Bell KM, Plon L, Bunney WE Jr, Potkin SG. S-adenosylmethionine treatment of depression: a controlled clinical trial. Am J Psychiatry 1988;145:1110-4. View abstract.

Bell KM, Potkin SG, Carreon D, Plon L. S-adenosylmethionine blood levels in major depression: changes with drug treatment. Acta Neurol Scand Suppl 1994;154:15-8. View abstract.

Berger R, Nowak H. A new medical approach to the treatment of osteoarthritis. Report of an open phase IV study with ademetionine (Gumbaral). Am J Med 1987;83:84-8. View abstract.

Berlanga C, Ortega-Soto HA, Ontiveros M, Senties H. Efficacy of S-adenosyl-L-methionine in speeding the onset of action of imipramine. Psychiatry Res 1992;44:257-62. View abstract.

Binder T., Salaj P., Zima T., Vitek L. [Ursodeoxycholic acid, S-adenosyl-L-methionine and their combinations in the treatment of gestational intrahepatic cholestasis (ICP)]. Ceska Gynekol 2006;71(2):92-98. View abstract.

Binder T., Salaj P., Zima T., Vitek L. Randomized prospective comparative study of ursodeoxycholic acid and S-adenosyl-L-methionine in the treatment of intrahepatic cholestasis of pregnancy. J Perinat Med 2006;34(5):383-391. View abstract.

Bombardieri G, Milani A, Bernardi L, et al. Effects of S-adenosyl-L-methionine (SAMe) in the treatment of Gilbert's syndrome. Curr Ther Res 1985;37(3):580-585.

Bottiglieri T, Hyland K, Reynolds EH. The clinical potential of ademetionine (S-adenosylmethionine) in neurological disorders. Drugs 1994;48:137-52. View abstract.

Bottiglieri T. S-Adenosyl-L-methionine (SAMe): from the bench to the bedside--molecular basis of a pleiotrophic molecule. Am J Clin Nutr 2002;76:1151S-7S. View abstract.

Bradley JD, Flusser D, Katz BP, et al. A randomized, double blind, placebo controlled trial of intravenous loading with S-adenosylmethionine (SAM) followed by oral SAM therapy in patients with knee osteoarthritis. J Rheumatol 1994;21:905-11. View abstract.

Buzzelli G., Moscarella S., Focardi G., Dattolo P., Giusti A., Calviani L., Relli P., Gentilini, P. [Ursodeoxycholic hemisuccinate in the treatment of chronic active hepatitis. A controlled clinico-therapeutic study]. Minerva Med 1992;83(9):537-540. View abstract.

Cacciatore L, Varriale A, Cozzolino G, et al. S-adenosylmethionine (SAMe) in the treatment of pruritus in chronic liver disease. Acta Therapeutica 1989;15:363-371.

Carney MW, Chary TK, Bottiglieri T, Reynolds EH. The switch mechanism and the bipolar/unipolar dichotomy. Br J Psychiatry 1989;154:48-51. View abstract.

Carrieri PB, Indaco A, Gentile S, et al. S-adenosylmethionine treatment of depressioin in patients with Parkinson's disease: a double-blind, crossover study versus placebo. Curr Ther Res 1990;48(1):154-60.

Caruso I, Pietrogrande V. Italian double-blind, multicenter study comparing S-adenosylmethionine, naproxen, and placebo in the treatment of degenerative joint disease. Am J Med 1987;83:66-71. View abstract.

Castagna A, Le Grazie C, Accordini A, et al. Cerebrospinal fluid S-adenosylmethionine (SAMe) and glutathione concentrations in HIV infection: effect of parenteral treatment with SAMe. Neurol 1995;45:1678-83. View abstract.

Ceccato S, Cucinotta D, Carapezzi C, et al. [Double-blind clinical study of the therapeutic effect of SAMe and Ibuprofen in degenerative osteoarticular pathology]. G Clin Med 1980;61(2):148-62. View abstract.

Charlton CG, Crowell B Jr. Parkinson's disease-like effects of S-adenosyl-L-methionine: effects of L-dopa. Pharmacol Biochem Behav 1992;43:423-31.. View abstract.

Chawla RK, Bonkovsky HL, Galambos JT. Biochemistry and pharmacology of S-adenosyl-L-methionine and rationale for its use in liver disease. Drugs 1990;40:98-110. View abstract.

Cibin M, Gentile N, Ferri M, and et al. S-adenosylmethionine (SAMe) is effective in reducing ethanol abuse in an outpatient program for alcoholics. In: Kuriyama K, Takada A, and Ishii H. Biomedical and social aspects of alcohol and alcoholism. Kyoto, Japan: Elsevier Science Publishers BV (Biomedical Division);1988.

Cowley G, Underwood A. Newsweek. July 5, 1999; pp. 46-50.

Czap A. Beware the son of SAMe. Altern Med Rev 1999;4:73. View abstract.

De Berardis D, Marini S, Serroni N, Rapini G, Iasevoli F, Valchera A, Signorelli M, Aguglia E, Perna G, Salone A, Di Iorio G, Martinotti G, Di Giannantonio M. S-Adenosyl-L-Methionine augmentation in patients with stage II treatment-resistant major depressive disorder: an open label, fixed dose, single-blind study. ScientificWorldJournal 2013;2013:204649. View abstract.

De Silva V, El-Metwally A, Ernst E, et al. Evidence for the efficacy of complementary and alternative medicines in the management of osteoarthritis: a systematic review. Rheumatology (Oxford) 2011;50(5):911-920. View abstract.

Delle Chiaie R, Pancheri P, Scapicchio P. Efficacy and tolerability of oral and intramuscular S-adenosyl-Lmethionine 1,4-butanedisulfonate (SAMe) in the treatment of major depression: comparison with imipramine in multicenter studies. Am J Clin Nutr 2002;76:1172S-6S. View abstract.

Dhediya RM, Joshi S, Gajbhiye SV, Jalgaonkar SV, Biswas M. Evaluation of antiepileptic activity of S-adenosylmethionine and its role in memory impairment in pentylenetetrazole-induced kindling model in rats. Epilepsy Behav 2016;61:153-7. View abstract.

Adeniyi, A. A., Brindley, G. S., Pryor, J. P., and Ralph, D. J. Yohimbine in the treatment of orgasmic dysfunction. Asian J Androl 2007;9(3):403-407. View abstract.

Albus, M., Zahn, T. P., and Breier, A. Anxiogenic properties of yohimbine. I. Behavioral, physiological and biochemical measures. Eur.Arch.Psychiatry Clin.Neurosci. 1992;241(6):337-344. View abstract.

Bagheri, H., Schmitt, L., Berlan, M., and Montastruc, J. L. Effect of 3 weeks treatment with yohimbine on salivary secretion in healthy volunteers and in depressed patients treated with tricyclic antidepressants. Br J Clin Pharmacol 1992;34(6):555-558. View abstract.

Berlin, I., Crespo-Laumonnier, B., Cournot, A., Landault, C., Aubin, F., Legrand, J. C., and Puech, A. J. The alpha 2-adrenergic receptor antagonist yohimbine inhibits epinephrine-induced platelet aggregation in healthy subjects. Clin Pharmacol.Ther. 1991;49(4):362-369. View abstract.

Boon, N. A., Elliott, J. M., Grahame-Smith, D. G., John-Green, T., and Stump, K. A comparison of alpha 2-adrenoreceptor binding characteristics of intact human platelets identified by [3H]-yohimbine and [3H]- dihydroergocryptine. J Auton.Pharmacol 1983;3(2):89-95. View abstract.

Braddock, L., Cowen, P. J., Elliott, J. M., Fraser, S., and Stump, K. Binding of yohimbine and imipramine to platelets in depressive illness. Psychol.Med 1986;16(4):765-773. View abstract.

Campbell-Tofte, J. I., Molgaard, P., Josefsen, K., Abdallah, Z., Hansen, S. H., Cornett, C., Mu, H., Richter, E. A., Petersen, H. W., Norregaard, J. C., and Winther, K. Randomized and double-blinded pilot clinical study of the safety and anti-diabetic efficacy of the Rauvolfia-Citrus tea, as used in Nigerian traditional medicine. J Ethnopharmacol. 1-27-2011;133(2):402-411. View abstract.

Charney, D. S., Heninger, G. R., and Sternberg, D. E. Assessment of alpha 2 adrenergic autoreceptor function in humans: effects of oral yohimbine. Life Sci 6-7-1982;30(23):2033-2041. View abstract.

Giampreti, A., Lonati, D., Locatelli, C., Rocchi, L., and Campailla, M. T. Acute neurotoxicity after yohimbine ingestion by a body builder. Clin Toxicol.(Phila) 2009;47(8):827-829. View abstract.

Landis, E. and Shore, E. Yohimbine-induced bronchospasm. Chest 1989;96(6):1424. View abstract.

Mann, K., Klingler, T., Noe, S., Roschke, J., Muller, S., and Benkert, O. Effects of yohimbine on sexual experiences and nocturnal penile tumescence and rigidity in erectile dysfunction. Arch.Sex Behav. 1996;25(1):1-16. View abstract.

Mustonen, P., Savola, J., and Lassila, R. Atipamezole, an imidazoline-type alpha(2)-adrenoceptor inhibitor, binds to human platelets and inhibits their adrenaline-induced aggregation more effectively than yohimbine. Thromb.Res 8-1-2000;99(3):231-237. View abstract.

Myers, A. and Barrueto, F., Jr. Refractory priapism associated with ingestion of yohimbe extract. J Med Toxicol. 2009;5(4):223-225. View abstract.

Riley AJ, Goodman R, Kellett JM, and et al. Double blind trial of yohimbine hydrochloride in the treatment of erection inadequacy. Sexual Marital Ther 1989;4(1):17-26.

Rowland, D. L., Kallan, K., and Slob, A. K. Yohimbine, erectile capacity, and sexual response in men. Arch Sex Behav 1997;26(1):49-62. View abstract.

Siddiqui, M. A., More-O'Ferrall, D., Hammod, R. S., Baime, R. V., and Staddon, A. P. Agranulocytosis associated with yohimbine use. Arch.Intern.Med 6-10-1996;156(11):1235-1237. View abstract.

Susset, J. G., Tessier, C. D., Wincze, J., Bansal, S., Malhotra, C., and Schwacha, M. G. Effect of yohimbine hydrochloride on erectile impotence: a double-blind study. J Urol. 1989;141(6):1360-1363. View abstract.

Swann, A. C. Mechanisms of impulsivity in bipolar disorder and related illness. Epidemiol.Psichiatr.Soc. 2010;19(2):120-130. View abstract.

Swann, A. C., Birnbaum, D., Jagar, A. A., Dougherty, D. M., and Moeller, F. G. Acute yohimbine increases laboratory-measured impulsivity in normal subjects. Biol.Psychiatry 5-15-2005;57(10):1209-1211. View abstract.

Achor RW, Hanson NO, Gifford RW Jr. Hypertension treated with Rauwolfia serpentina (whole root) and with reserpine; controlled study disclosing occasional severe depression. J Am Med Assoc. 1955 Oct 29;159(9):841-5. View abstract.

Azmi MB, Qureshi SA, Haseen Ahmed SD, et al. Therapeutic role of Rauwolfia serpentina in minimizing the risk of glycosylation and associated biomarkers in experimentally induced type 1 diabetic mice. Pak J Pharm Sci 2021;34(1):69-76. View abstract.

Azmi MB, Qureshi SA. Methanolic Root Extract of Rauwolfia serpentina Benth Improves the Glycemic, Antiatherogenic, and Cardioprotective Indices in Alloxan-Induced Diabetic Mice. Adv Pharmacol Sci. 2012;2012:376429. View abstract.

Azmi MB, Qureshi SA. Rauwolfia serpentina improves altered glucose and lipid homeostasis in fructose-induced type 2 diabetic mice. Pak J Pharm Sci. 2016 Sep;29(5):1619-1624. View abstract.

Bharucha AE, Skaar T, Andrews CN, et al Relationship of cytochrome P450 pharmacogenetics to the effects of yohimbine on gastrointestinal transit and catecholamines in healthy subjects. Neurogastroenterol Motil. 2008;20(8):891-9. View abstract.

Briggs GB, Freeman RK, Yaffe SJ. Drugs in Pregnancy and Lactation. 5th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 1998.

Dey A, Pandey DK. HPTLC detection of altitudinal variation of the potential antivenin stigmasterol in different populations of the tropical ethnic antidote Rauvolfia serpentina. Asian Pac J Trop Med. 2014 Sep;7S1:S540-5. View abstract.

Eurlings MC, Lens F, Pakusza C, Peelen T, Wieringa JJ, Gravendeel B. Forensic identification of Indian snakeroot (Rauvolfia serpentina Benth. ex Kurz) using DNA barcoding. J Forensic Sci. 2013 May;58(3):822-30. View abstract.

Ezeigbo II, Ezeja MI, Madubuike KG, Ifenkwe DC, Ukweni IA, Udeh NE, Akomas SC. Antidiarrhoeal activity of leaf methanolic extract of Rauwolfia serpentina. Asian Pac J Trop Biomed. 2012 Jun;2(6):430-2. doi: 10.1016/S2221-1691(12)60070-7. View abstract.

Foster S, Tyler VE. Tyler's Honest Herbal, 4th ed., Binghamton, NY: Haworth Herbal Press, 1999.

Herman AM, Critchley HD, Duka T. The impact of yohimbine-induced arousal on facets of behavioural impulsivity. Psychopharmacology (Berl). 2019;236(6):1783-1795. View abstract.

Hollander E, McCarley A. Yohimbine treatment of sexual side effects induced by serotonin reuptake blockers. J Clin Psychiatry 1992;53:207-9. View abstract.

Jacobsen FM. Fluoxetine-induced sexual dysfunction and an open trial of yohimbine. J Clin Psychiatry 1992;53:119-22. View abstract.

Kearney T, Tu N, Haller C. Adverse drug events associated with yohimbine-containing products: a retrospective review of the California Poison Control System reported cases. Ann Pharmacother 2010;44:1022-9. View abstract.

Kuehl LK, Deuter CE, Hellmann-Regen J, Kaczmarczyk M, Otte C, Wingenfeld K. Enhanced noradrenergic activity by yohimbine and differential fear conditioning in patients with major depression with and without adverse childhood experiences. Prog Neuropsychopharmacol Biol Psychiatry. 2020;96:109751. View abstract.

Kumar S, Singh A, Bajpai V, Srivastava M, Singh BP, Ojha S, Kumar B. Simultaneous Determination of Bioactive Monoterpene Indole Alkaloids in Ethanolic Extract of Seven Rauvolfia Species using UHPLC with Hybrid Triple Quadrupole Linear Ion Trap Mass Spectrometry. Phytochem Anal. 2016 Sep;27(5):296-303. View abstract.

Lobay D. Rauwolfia in the Treatment of Hypertension. Integr Med (Encinitas). 2015 Jun;14(3):40-6. View abstract.

Lowinger P. Rauwolfia serpentina in the control of anxiety. Psychiatr Q. 1957 Jul;31(3):445-53. View abstract.

Metz S, Waiblinger-Grigull T, Schulreich S, et al. Effects of hydrocortisone and yohimbine on decision-making under risk. Psychoneuroendocrinology. 2020;114:104589. View abstract.

Milman N, Scheibel J, Jessen O. Lysine prophylaxis in recurrent herpes simplex labialis: a double-blind, controlled crossover study. Acta Derm Venereol 1980;60:85-7. View abstract.

Pathania S, Randhawa V, Bagler G. Prospecting for novel plant-derived molecules of Rauvolfia serpentina as inhibitors of Aldose Reductase, a potent drug target for diabetes and its complications. PLoS One. 2013 Apr 17;8(4):e61327. View abstract.

Rani PU, Naidu MU. Subjective and polysomnographic evaluation of a herbal preparation in insomnia. Phytomedicine 1998;5:253-7.

Ruck B, Shih RD, Marcus SM. Hypertensive crisis from herbal treatment of impotence. Am J Emerg Med. 1999;17:317-318.

Ryan JJ, Hanes DA, Corroon J, Taylor J, Bradley R. Prospective safety evaluation of a cardiovascular health dietary supplement in adults with prehypertension and stage I hypertension. J Altern Complement Med 2019;25(2):249-56. doi:10.1089/acm.2018.0311. View abstract.

Sagi S, Avula B, Wang YH, Khan IA. Quantification and characterization of alkaloids from roots of Rauwolfia serpentina using ultra-high performance liquid chromatography-photo diode array-mass spectrometry. Anal Bioanal Chem. 2016 Jan;408(1):177-90. View abstract.

Sandler B, Aronson P. Yohimbine-induced cutaneous drug eruption, progressive renal failure, and lupus-like syndrome. Urol 1993;41:343-5. View abstract.

Schmauss M, Laakmann G, Dieterle D. Effects of alpha 2-receptor blockade in addition to tricyclic antidepressants in therapy-resistant depression. J Clin Psychopharmacol. 1988;8(2):108-11. View abstract.

Sheldon MB, Kotte JH. Effect of Rauwolfia serpentina and reserpine on the blood pressure in essential hypertension; a long-term double-blind study. Circulation. 1957 Aug;16(2):200-6. View abstract.

Teloken C, Rhoden EL, Sogari P, et al. Therapeutic effects of high dose yohimbine hydrochloride on organic erectile dysfunction. J Urol 1998;159:122-4. View abstract.

Vakil RJ. A clinical trial of Rauwolfia serpentina in essential hypertension. Br Heart J. 1949 Oct;11(4):350-5. View abstract.

VandenBrink, B. M., Foti, R. S., Rock, D. A., Wienkers, L. C., and Wahlstrom, J. L. Prediction of CYP2D6 drug interactions from in vitro data: evidence for substrate-dependent inhibition. Drug Metab Dispos. 2012;40(1):47-53. View abstract.

Wang N, Xie YW, Li MY, et al. Simultaneous determination of five alkaloids from Rauvolfia vomitoria in rat plasma by LC-MS/MS: Application to a comparative pharmacokinetic study in normal and type 2 diabetic rats. J Sep Sci 2021;44(7):1391-1403. View abstract.

Wilkins RW, Judson WE. The use of Rauwolfia serpentina in hypertensive patients. N Engl J Med. 1953 Jan 8;248(2):48-53. View abstract.

Wylie KR. Yohimbine and sinusitis. Br J Psychiatry. 1996;169(3):384-5. View abstract.

Young DS. Effects of Drugs on Clinical Laboratory Tests 4th ed. Washington: AACC Press, 1995.

CONDITIONS OF USE AND IMPORTANT INFORMATION: This information is meant to supplement, not replace advice from your doctor or healthcare provider and is not meant to cover all possible uses, precautions, interactions or adverse effects. This information may not fit your specific health circumstances. Never delay or disregard seeking professional medical advice from your doctor or other qualified health care provider because of something you have read on WebMD. You should always speak with your doctor or health care professional before you start, stop, or change any prescribed part of your health care plan or treatment and to determine what course of therapy is right for you.

This copyrighted material is licensed from Therapeutic Research Center, LLC. Information from this source is evidence-based and objective, and without commercial influence. For professional medical information on natural medicines, see Natural Medicines Comprehensive Database Professional Version.
Licensed from Therapeutic Research Center, LLC
Copyright © 1995-2024 by Therapeutic Research Center, LLC. All Rights Reserved.

INDIAN SNAKEROOT - Uses, Side Effects, and More

Overview

Uses & Effectiveness

Side Effects

Special Precautions and Warnings

Interactions

Major Interaction

Digoxin (Lanoxin) interacts with INDIAN SNAKEROOT

Levodopa interacts with INDIAN SNAKEROOT

Medications for mental conditions (Antipsychotic drugs) interacts with INDIAN SNAKEROOT

Medications for high blood pressure (Beta-blockers) interacts with INDIAN SNAKEROOT

Moderate Interaction

Ephedrine interacts with INDIAN SNAKEROOT

Medications for depression (MAOIs) interacts with INDIAN SNAKEROOT

Sedative medications (CNS Depressants) interacts with INDIAN SNAKEROOT

Stimulant drugs interacts with INDIAN SNAKEROOT

Medications changed by the liver (Cytochrome P450 2D6 (CYP2D6) substrates) interacts with INDIAN SNAKEROOT

Medications for diabetes (Antidiabetes drugs) interacts with INDIAN SNAKEROOT

Medications for high blood pressure (Antihypertensive drugs) interacts with INDIAN SNAKEROOT

Medications that slow blood clotting (Anticoagulant / Antiplatelet drugs) interacts with INDIAN SNAKEROOT

Medications for depression (Tricyclic Antidepressants) interacts with INDIAN SNAKEROOT

Dosing